CloudHealth Technologies Expands Business in Europe
CloudHealth Technologies, the leader in cloud service management, today announced that it is expanding its customer base, partner list and business operations in the European region. Helping to fuel the expansion is $46 million in Series D funding, which the company secured in June. The funding round will help CloudHealth Technologies scale international operations and double the size of its global workforce.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170720005189/en/
CloudHealth Technologies Expands Business in Europe (Photo: Business Wire)
Cloud adoption in EMEA is growing steadily, with the market projected to reach €44.8 billion by the year 2020, according to Market Research & Statistics1. As enterprises turn to the cloud to build apps and manage operations, they improve productivity but, at the same time, face challenges dealing with cloud complexity and managing cost.
“It comes as no surprise that public cloud adoption is accelerating in the European market, given its reputation as a hotbed for technology innovation” said Larry Begley, CFO of CloudHealth Technologies. “Enterprises in the UK and across EMEA are using CloudHealth for visibility into their cloud resources. This allows them to cut costs, improve performance, manage risks, migrate workloads and set policies. Over the next few years, our local presence will continue to grow in order to support our global customers and partners.”
In the past twelve months, CloudHealth Technologies has grown its number of direct customers in EMEA by 72 percent. During that same period, the number of partners for the region increased by 500 percent. To support this continued growth, CloudHealth Technologies has opened offices in Amsterdam and in Tel Aviv, where it counts three of the top Israeli service providers as partners: CloudZone, DoIT and AllCloud. The company also moved to an expanded office in central London, with a local workforce that will look to double by year-end 2017.
In-region event participation will continue to be a focus. Earlier this year, local cloud leaders gathered together for a CloudHealth Connect community event in London to discuss cloud challenges and best practices related to cost management, scale, security and governance. CloudHealth Technologies also exhibited at AWS Summits in London and Tel Aviv, and participated in the Cape Town Summit with partner First Distribution. During these events, booth visitors learned about the latest platform enhancements and met with cloud management experts.
“The cloud is an incredible business enabler, but scaling it can be a challenge without proper visibility,” said Tyrone Forbes, Senior Capacity and Performance Manager, EE. “When we looked for a way to optimize our AWS environment, CloudHealth was the obvious choice. It helps us control cost and usage, as well as manage thousands of EC2 instances.”
“We’re seeing huge interest in strategic cloud services, and our mission is to help others sell these services as quickly as possible,” said Russell Warne, AWS Lead at First Distribution, a CloudHealth Technologies partner based in South Africa. “CloudHealth is simply one of the strongest levers we offer. Even a new entrant can start adding significant value to customers in an incredibly short space of time.”
CloudHealth Technologies’ list of EMEA customers includes EE, Elastera, Financial Times, Funding Circle, Telefonica, Transport for London and Randstad. CloudHealth has also added many EMEA service providers to its growing Cloud Business Accelerator Program. New partners include ACA IT-Solutions, AllCloud, ANS Group, CDW, DoIT, HeleCloud, PA Consulting, Rebura LTD, Sopra Steria, Softcat plc, Storm Reply and Taldor Cloud market.
To learn more, visit www.cloudhealthtech.com.
Additional background
- Blog: Financial Times: Gamifying Cost Optimization with CloudHealth
- Case study: The Economist’s Big Move to the Cloud with Help from Cloudreach and CloudHealth
- Video: NewCloudViews -- Elastera
- Video: NewCloudViews -- Cloudreach
About CloudHealth Technologies
CloudHealth, the recognized worldwide leader in the growing Cloud Service Management industry, provides integrated reporting, recommendations and active policy management to help companies control the problems associated with “cloud chaos.” Our comprehensive platform gives enterprise companies and MSPs the ability to visualize, optimize and govern their cloud and hybrid environments. By providing analysis and deep insight into historical trends, capacity planning, resource optimization and resource automation, CloudHealth enables stakeholders ranging from C-level executives to engineers, cloud specialists, architects, IT directors and LOB managers to improve performance and drive value through their cloud ecosystems. Well-known organizations that rely on CloudHealth’s capabilities and expertise include Amtrak, Dow Jones, Acquia, and Sumo Logic, among others. Based in Boston, the company is backed by Kleiner Perkins, Meritech Capital Partners, Sapphire Ventures, Scale Venture Partners, .406 Ventures and Sigma Prime Ventures. For continuous product updates, industry news and engagement visit us at www.cloudhealthtech.com or follow us @cloudhealthtech.
1 Telecom News, April 24, 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170720005189/en/
Contact information
PAN Communications
Mike O’Connell or Lisa Sorrentino, 617-502-4300
cloudhealth@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom